Reid v. SmithKline Beecham Corp.

366 F. Supp. 2d 989, 2005 U.S. Dist. LEXIS 11188, 2005 WL 995563
CourtDistrict Court, S.D. California
DecidedApril 11, 2005
Docket3:03-cv-01780
StatusPublished
Cited by3 cases

This text of 366 F. Supp. 2d 989 (Reid v. SmithKline Beecham Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Reid v. SmithKline Beecham Corp., 366 F. Supp. 2d 989, 2005 U.S. Dist. LEXIS 11188, 2005 WL 995563 (S.D. Cal. 2005).

Opinion

ORDER GRANTING IN PART AND DENYING IN PART DEFENDANT’S MOTION FOR SUMMARY JUDGMENT; DENYING PLAINTIFF’S CROSS-MOTION FOR SUMMARY JUDGMENT

WHELAN, District Judge.

On July 18, 2003 Yvonne Reid (“Plaintiff’ or “Reid”) commenced this employment action in San Diego Superior Court. Shortly thereafter, Defendant Glaxos-mithkline (“Defendant” or “GSK”) removed the action to federal court. Currently pending before the Court are the parties’ cross-motions for summary judgment. The Court decides the matter on the papers submitted and without oral argument pursuant to Civil Local Rule 7.1(d.l). For the reasons stated below, the Court DENIES Plaintiffs summary judgment motion and GRANTS in part and DENIES in part Defendant’s summary judgment motion.

I. Background

Plaintiff began working for GSK on January 2, 1989 as a pharmaceutical sales representative in Oklahoma. Sometime in 1993, GSK transferred Plaintiff to San Diego where she worked in various divisions and positions. In September 2002 GSK assigned Plaintiff to GSK’s Oncology Division as a Senior Executive Oncology Account Manager for Acute Care where she would be responsible for selling four drugs: Zofran, Argatroban, Navelbine and Hycamtin. Plaintiffs assignment was effective immediately, but GSK expected transfers to its Oncology Division to continue working in their previous positions for three months while they underwent the necessary training for their new positions.

In October 2002 Reid informed GSK’s Employee Response Center 1 that she was pregnant and that she anticipated she would need to take leave beginning in January 2003. In November 2002 GSK conducted a two and a half week training program on Hycamtin and Navelbine for transfers to the Oncology division. Because she was pregnant, Reid did not attend this training. On December 1, 2002 Reid took over as Senior Executive Oncology Account Manager. Approximately one month later, she began her twelve weeks of maternity leave.

Reid returned from maternity leave on March 31, 2003. Three days after Reid returned to work, her immediate supervisor, Scott Barnes (“Barnes”), informed her of a training session in Philadelphia on Hycamtin and Navelbine scheduled for May 6 through 21. Reid responded that it was impossible for her to attend the training because she had an eleven week old *992 infant. Reid reiterated this to Barnes several days later in an email message, stating that “due to the fact that I have an eleven week old infant presents a number of issues which make it impossible for me to attend this training.” (Declaration of Yvonne Beid, Ex. A).

Several days later, while at a training meeting for the launch of a new drug, Barnes informed Reid that she was required to attend the Philadelphia training. Reid again told Barnes that she would not be able to attend the training because of her newborn child and again asked to be excused from the training. (.Deposition of Yvonne Reid at 143:5-19). In response, Barnes told Reid that “they feel you have already had enough time off.” (Deposition of Scott Barnes at 143:13-15).

Over the next several weeks, GSK personnel attempted to work with Reid to address her concerns regarding attending the Philadelphia training. GSK offered to (1) allow Reid to bring her son and his caregiver to Philadelphia; (2) allow Reid to take as many lactation breaks as needed during the training day; (3) allow her to use the lactation rooms at the training site; (4) pay for a larger hotel room to accommodate childcare; (5) provide a refrigerator to store milk; and (6) provide a replacement caregiver at a discount if Reid elected not to bring her son’s normal caregiver. (Reid Depo., Ex. 19). GSK also offered to cut Reid’s expected training time from 17 to 7 days and to move her final videotape role play for the Hycamtin class from May 12th to May 9th. (Declaration of Bruce Rosvold ¶¶ 18-20).

When despite these accommodations Reid still indicated that she would not attend the training, GSK informed her on May 2, 2003, via a memo from a Human Resources Manager named Mary Kate Harkins (“Harkins”), that if she failed to attend the Philadelphia training GSK would assume she was voluntarily resigning from her job. {Reid Decl, Ex. C). Reid immediately responded to Harkins via email that she was not resigning and requested that she be notified in writing if GSK would terminate her for failing to attend the training. {Reid Decl, Ex. D). Despite receiving this email message, Har-kins never responded to it. {Deposition of Mary Kate Harkins at 236:21-238:9). Nor did anyone else from GSK advise Reid that she would be terminated for not attending the Philadelphia training until she was actually terminated. {Reid Decl. ¶ 43). 2

On May 7, several days into the training, Harkins called Barnes and told him to set up a conference call for May 9 between the two of them and Reid. {Barnes Depo. 154:8-156:1; 160:9-164:5; 165:12-17, Ex. 2). During this May 7 call, Harkins told Barnes that the purpose of the May 9 call was to inform Reid that she was being terminated for job abandonment. Id. According to Harkins, GSK could terminate Reid for job abandonment on May 9 because as of that date she would have missed the required five consecutive days of work. Id. On May 9, 2003 Harkins and Barnes informed Reid that she was being terminated for abandoning her job. {Reid Decl. ¶ 47).

II. Legal Standard

Summary judgment is appropriate under Rule 56 of the Federal Rules of Civil Procedure if the moving party demonstrates the absence of a genuine issue of material fact and entitlement to judgment as a matter of law. See Fed.R.Civ.P. 56(c); *993 Celotex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). A fact is material when, under the governing substantive law, it could affect the outcome of the case. See Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986); Freeman v. Arpaio, 125 F.3d 732, 735 (9th Cir.1997). A dispute is genuine if a reasonable jury could return a verdict for the nonmoving party. See Anderson, 477 U.S. at 248, 106 S.Ct. 2505. Summary judgment is appropriate when a party cannot meet an essential element of its claim or defense. Nissan Fire & Marine Ins. Co. v. Fritz Cos., 210 F.3d 1099, 1103 (9th Cir.2000).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Szarowicz v. Birenbaum
California Court of Appeal, 2020
Brandon v. Rite Aid Corp., Inc.
408 F. Supp. 2d 964 (E.D. California, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
366 F. Supp. 2d 989, 2005 U.S. Dist. LEXIS 11188, 2005 WL 995563, Counsel Stack Legal Research, https://law.counselstack.com/opinion/reid-v-smithkline-beecham-corp-casd-2005.